Clinical Trial Update: Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) [Phase 2]

View source ↗

Summary

Phase 2 trial ALTER-PA-001 is evaluating a combination of Anlotinib, Benmelstobart, and AG as first-line therapy for advanced metastatic pancreatic cancer. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AG
• Anlotinib (anlotinib)
• Benmelstobart

Snippet

Sponsor: RenJi Hospital | Conditions: Pancreatic Cancer, First-line | Phase 2 | Status: NOT_YET_RECRUITING